Program
Recombinant Super-compound Interferon
Also written as “rSIFN-co Nasal Spray”, “rSIFN-co” and “Recombinant Super-Compound Interferon (rSIFN-co)”.
Its studies are mostly in Rectal Neoplasms · COVID-19 · Neuroendocrine Tumors · Carcinoma, Non-Small-Cell Lung, led by Sichuan Huiyang Life Science and Technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Huiyang Life Science and Technology | 41 open or running | phase 2since Jun 16, 2022 | Feb 6, 2015 | Jan 2030phase 2 · NCT07662278 |
Also a collaborator on its studies: medelis-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 6, 2015First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT02387307 · 42 enrolled · Singapore
- Jun 3, 2015Phase 1 study in Neuroendocrine TumorsNCT02464007 · 7 enrolled · United States
- Jun 16, 2022Phase 2 study in COVID-19NCT05485584 · 188 enrolled · Philippines
- Jun 16, 2026Phase 2 study in Mid-low Locally Advanced Rectal CancerNCT07662278 · 90 planned
Ahead
- Jan 2030Primary completion: phase 2 study in Mid-low Locally Advanced Rectal CancerNCT07662278
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07662278Mid-low Locally Advanced Rectal Cancer | 2 | Not yet recruiting | Jan 2030 | 90 |
| NCT05485584COVID-19 · Philippines | 2 | Completed | Apr 5, 2023 | 188 |
| NCT02464007Neuroendocrine Tumors · United States | 1 | Terminated | Nov 2024 | 7 |
| NCT02387307Carcinoma, Non-Small-Cell Lung · Singapore | 1 | Completed | Jun 2018 | 42 |
How it is read
Names in the registry
- “rSIFN-co Nasal Spray”, 2 entries
- “rSIFN-co”, 2 entries
- “Recombinant Super-Compound Interferon (rSIFN-co)”, 1 entry
Conditions, from the studies’ own filings
- Rectal Neoplasms, 1 study
- COVID-19, 1 study
- Neuroendocrine Tumors, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.